Bezmialem Vakf Üniversitesi

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Obesity2 trials
• Ulcerative colitis2 trials
• Crohn's disease1 trial
• Lung cancer1 trial
• Vitiligo1 trial

Phase

• Phase 34 trials
• Phase 21 trial

Status

• Recruiting4 trials
• Active, not recruiting1 trial

Lead sponsor

• Eli Lilly and Company4 trials
• Pfizer1 trial

Running trials

• Recruiting

  LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Phase 2· Eli Lilly and Company· Source

  Contact: Metin Basaranoglu (principal investigator)

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Eli Lilly and Company· Source

  Contact: Metin Basaranoglu (principal investigator)

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Eli Lilly and Company· Source

  Contact: Metin Basaranoglu (principal investigator)

• Recruiting

  A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  NCT06119581· Phase 3· Eli Lilly and Company· Source

  Contact: Haci Mehmet Turk (principal investigator)

• Active, not recruiting

  A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

  NCT06072183· Phase 3· Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity2 recruiting
• Ulcerative colitis2 recruiting
• Crohn's disease1 recruiting
• Lung cancer1 recruiting